Sign in

Research summary ·

A Systematic Review of Apremilast as a Therapeutic Option for Lichen Planus.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This review looked at the drug apremilast for lichen planus. The team asked how well it worked and how safe it was. They searched PubMed, EMBASE and Cochrane CENTRAL up to July 2024. From the articles they found, 6 studies with 17 people were used. They also looked at dose, time on the drug and other treatments.

What they found

Of the 17 people, 12 were women, and mouth disease was the most common type. In 5 of 15 people with mouth disease, the disease went quiet, called remission. Remission also came in the one gullet case and the one mouth-and-skin case. Disease getting worse was the main reason people stopped the drug. No life-threatening side effects were reported. All 7 people with remission were women, and 6 needed under 6 months.

What it means for patients

The authors say apremilast may work well on its own for lichen planus. They saw this mainly for mouth disease that other treatments had not helped. They also say the drug was mostly well tolerated. In 6 of 7 people with remission, no other treatment was needed.

Why it is not certain yet

The review had only 17 people, a small number. Doses varied between the studies. There was little follow-up data. No data were given on relapse or long-term results. The authors say more studies are needed to know the drug's role. A review can only be as good as the studies in it.

Source

A Systematic Review of Apremilast as a Therapeutic Option for Lichen Planus.

PubMed · PMID 42296289

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Lichen planus publications